About CytoVale
CytoVale is a company based in San Francisco (United States) founded in 2013.. CytoVale has raised $206.78 million across 15 funding rounds from investors including HHS, CPP Investments and Norwest Venture Partners. The company has 115 employees as of December 31, 2024. CytoVale offers products and services including IntelliSep Sepsis Test. CytoVale operates in a competitive market with competitors including OpGen, Avails Medical, SphingoTec, Abionic and NOWDiagnostics, among others.
- Headquarter San Francisco, United States
- Employees 115 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cytovale Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$206.78 M (USD)
in 15 rounds
-
Latest Funding Round
$100 M (USD), Series D
Oct 11, 2024
-
Investors
HHS
& 12 more
-
Employee Count
115
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CytoVale
CytoVale offers a comprehensive portfolio of products and services, including IntelliSep Sepsis Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Rapid test assesses sepsis risk using white blood cell analysis.
Unlock access to complete
Unlock access to complete
Funding Insights of CytoVale
CytoVale has successfully raised a total of $206.78M across 15 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Series D — $100.0M
-
First Round
First Round
(01 Jul 2013)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series D - CytoVale | Valuation | Sands Capital | |
| Nov, 2023 | Amount | Series C - CytoVale | Valuation | Norwest Venture Partners | |
| Feb, 2022 | Amount | Grant - CytoVale | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CytoVale
CytoVale has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, CPP Investments and Norwest Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Founded Year | Domain | Location | |
|
Venture debt is provided globally across multiple sectors.
|
Founded Year | Domain | Location | |
|
Early-stage investments in science-driven companies are made.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CytoVale
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CytoVale
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytovale Comparisons
Competitors of CytoVale
CytoVale operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, Avails Medical, SphingoTec, Abionic and NOWDiagnostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| domain | founded_year | HQ Location |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| domain | founded_year | HQ Location |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Point-of-care diagnostic tools for allergy profiles are provided.
|
|
| domain | founded_year | HQ Location |
Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cytovale
Frequently Asked Questions about CytoVale
When was CytoVale founded?
CytoVale was founded in 2013.
Where is CytoVale located?
CytoVale is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is CytoVale a funded company?
CytoVale is a funded company, having raised a total of $206.78M across 15 funding rounds to date. The company's 1st funding round was a Grant of $9M, raised on Jul 01, 2013.
How many employees does CytoVale have?
As of Dec 31, 2024, the latest employee count at CytoVale is 115.
What does CytoVale do?
CytoVale is focussed on developing biomarkers for the early detection of sepsis, an infectious reaction that can lead to lung, kidney and liver failure. Its technology is based on the mechanical properties of individual cells (mechanomics). The instrument uses microfluidics to route and physically probe individual cells and claims to have the capacity to measure over 10 biophysical cell markers at rates above 2k cells per second, providing a high-throughput detection of the disease.
Who are the top competitors of CytoVale?
CytoVale's top competitors include Abionic, Avails Medical and SphingoTec.
What products or services does CytoVale offer?
CytoVale offers IntelliSep Sepsis Test.
Who are CytoVale's investors?
CytoVale has 13 investors. Key investors include HHS, CPP Investments, Norwest Venture Partners, Western Technology Investment, and EMV Capital.